Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EOLS NASDAQ:LXRX NASDAQ:NERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEOLSEvolus$7.08+5.0%$6.07$3.86▼$10.20$464.58M1.341.07 million shs76,808 shsLXRXLexicon Pharmaceuticals$2.26+4.8%$1.96$0.77▼$2.53$1.01B1.072.67 million shs296,623 shsNERVMinerva Neurosciences$4.33-0.5%$5.43$1.57▼$12.46$201.74M-0.18187,786 shs5,040 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEOLSEvolus+2.28%+1.66%+10.67%+54.23%-28.14%LXRXLexicon Pharmaceuticals+0.47%+10.77%0.00%+28.57%+194.24%NERVMinerva Neurosciences-6.65%-0.46%-17.30%-28.69%+145.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEOLSEvolus$7.08+5.0%$6.07$3.86▼$10.20$464.58M1.341.07 million shs76,808 shsLXRXLexicon Pharmaceuticals$2.26+4.8%$1.96$0.77▼$2.53$1.01B1.072.67 million shs296,623 shsNERVMinerva Neurosciences$4.33-0.5%$5.43$1.57▼$12.46$201.74M-0.18187,786 shs5,040 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEOLSEvolus+2.28%+1.66%+10.67%+54.23%-28.14%LXRXLexicon Pharmaceuticals+0.47%+10.77%0.00%+28.57%+194.24%NERVMinerva Neurosciences-6.65%-0.46%-17.30%-28.69%+145.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEOLSEvolus 2.50Moderate Buy$16.00126.15% UpsideLXRXLexicon Pharmaceuticals 2.33Hold$4.55100.97% UpsideNERVMinerva Neurosciences 2.00Hold$10.50142.49% UpsideCurrent Analyst Ratings BreakdownLatest LXRX, NERV, and EOLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026LXRXLexicon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/17/2026EOLSEvolus BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.006/15/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/13/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026LXRXLexicon Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$2.30 ➝ $3.104/24/2026EOLSEvolus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/15/2026NERVMinerva Neurosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$14.003/27/2026NERVMinerva Neurosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEOLSEvolus$297.18M1.57N/AN/A($0.36) per share-19.65LXRXLexicon Pharmaceuticals$69.64M14.44N/AN/A$0.30 per share7.55NERVMinerva NeurosciencesN/AN/AN/AN/A($3.25) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEOLSEvolus-$51.64M-$0.67N/A117.92N/A-14.39%N/A-19.03%8/4/2026 (Estimated)LXRXLexicon Pharmaceuticals-$50.34M-$0.07N/AN/AN/A-37.46%-18.64%-11.79%8/5/2026 (Estimated)NERVMinerva Neurosciences-$293.42M-$29.16N/A0.90N/AN/AN/A-32.63%8/13/2026 (Estimated)Latest LXRX, NERV, and EOLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026LXRXLexicon Pharmaceuticals-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million5/5/2026Q1 2026NERVMinerva Neurosciences-$0.13-$0.17-$0.04-$2.86N/AN/A5/4/2026Q1 2026EOLSEvolus-$0.14-$0.16-$0.02-$0.16$72.52 million$73.14 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEOLSEvolusN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEOLSEvolusN/A2.041.68LXRXLexicon Pharmaceuticals0.2418.8018.77NERVMinerva NeurosciencesN/A17.6517.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEOLSEvolus90.69%LXRXLexicon Pharmaceuticals74.70%NERVMinerva Neurosciences34.56%Insider OwnershipCompanyInsider OwnershipEOLSEvolus5.00%LXRXLexicon Pharmaceuticals14.00%NERVMinerva Neurosciences1.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEOLSEvolus17065.86 million62.56 millionOptionableLXRXLexicon Pharmaceuticals140444.20 million382.01 millionOptionableNERVMinerva Neurosciences946.59 million45.80 millionNot OptionableLXRX, NERV, and EOLS HeadlinesRecent News About These CompaniesMinerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 50-Day Moving Average - Here's WhyJune 24 at 4:07 AM | americanbankingnews.comMinerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline ProgramsJune 1, 2026 | globenewswire.comMinerva Neurosciences Launches ATM Offering to Fund TrialMay 27, 2026 | tipranks.comAll You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to BuyMay 20, 2026 | zacks.comMinerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 20, 2026 | zacks.comMinerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare ConferenceMay 18, 2026 | globenewswire.comMinerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesMay 5, 2026 | finanznachrichten.deMinerva Neurosciences Provides First Quarter 2026 Financial Results and Business UpdatesMay 5, 2026 | globenewswire.comMinerva Neurosciences (NERV) price target increased by 31.03% to 9.69April 28, 2026 | msn.comCitizens Initiates Coverage of Minerva Neurosciences (NERV) with Market Outperform RecommendationApril 16, 2026 | msn.comMinerva launched with New Outperform at Citizens on schizophrenia candidateApril 15, 2026 | seekingalpha.comMinerva Neurosciences Sets 2026 Annual Shareholder Meeting TimelineApril 6, 2026 | tipranks.comMinerva Announces Leadership TransitionApril 2, 2026 | globenewswire.comMinerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of SchizophreniaMarch 31, 2026 | globenewswire.comMinerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of SchizophreniaMarch 31, 2026 | seekingalpha.comMinerva Neurosciences (NERV) price target increased by 61.11% to 7.40March 27, 2026 | msn.comMinerva Neurosciences, Inc: Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026March 25, 2026 | finanznachrichten.deMinerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026March 25, 2026 | globenewswire.comMinerva Neurosciences to Participate in The Stifel 2026 Virtual CNS ForumMarch 12, 2026 | globenewswire.comMinerva Neurosciences, Inc: Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business UpdatesMarch 11, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 2026AI Can’t Reach the Real World Without These 3 StocksBy Thomas Hughes | May 27, 2026LXRX, NERV, and EOLS Company DescriptionsEvolus NASDAQ:EOLS$7.07 +0.33 (+4.90%) As of 10:02 AM Eastern This is a fair market value price provided by Massive. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Lexicon Pharmaceuticals NASDAQ:LXRX$2.26 +0.11 (+4.86%) As of 10:02 AM Eastern This is a fair market value price provided by Massive. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Minerva Neurosciences NASDAQ:NERV$4.32 -0.03 (-0.67%) As of 10:01 AM Eastern This is a fair market value price provided by Massive. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning Why nVent Could Be a Long-Term AI Infrastructure Winner These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
